Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 1
2006 2
2007 2
2008 1
2011 2
2012 4
2013 3
2014 2
2015 3
2016 8
2017 3
2018 2
2019 2
2020 2
2021 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Durie BGM, Hoering A, Sexton R, Abidi MH, Epstein J, Rajkumar SV, Dispenzieri A, Kahanic SP, Thakuri MC, Reu FJ, Reynolds CM, Orlowski RZ, Barlogie B. Durie BGM, et al. Among authors: reu fj. Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8. Blood Cancer J. 2020. PMID: 32393732 Free PMC article. Clinical Trial.
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM, Hoering A, Abidi MH, Rajkumar SV, Epstein J, Kahanic SP, Thakuri M, Reu F, Reynolds CM, Sexton R, Orlowski RZ, Barlogie B, Dispenzieri A. Durie BGM, et al. Among authors: reu f. Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23. Lancet. 2017. PMID: 28017406 Free PMC article. Clinical Trial.
NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016.
Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Anderson KC, et al. Among authors: reu fj. J Natl Compr Canc Netw. 2016 Apr;14(4):389-400. doi: 10.6004/jnccn.2016.0046. J Natl Compr Canc Netw. 2016. PMID: 27059188 Free PMC article.
Therapeutic Targeting of Protein Disulfide Isomerase PDIA1 in Multiple Myeloma.
Hasipek M, Grabowski D, Guan Y, Alugubelli RR, Tiwari AD, Gu X, DeAvila GA, Silva AS, Meads MB, Parker Y, Lindner DJ, Saunthararajah Y, Shain KH, Maciejewski JP, Reu FJ, Phillips JG, Jha BK. Hasipek M, et al. Among authors: reu fj. Cancers (Basel). 2021 May 28;13(11):2649. doi: 10.3390/cancers13112649. Cancers (Basel). 2021. PMID: 34071205 Free PMC article.
Daratumumab proves safe and highly effective in AL amyloidosis.
Khouri J, Kin A, Thapa B, Reu FJ, Bumma N, Samaras CJ, Liu HD, Karam MA, Reed J, Mathur S, Faiman BM, Devries G, Zonder J, Valent J. Khouri J, et al. Among authors: reu fj. Br J Haematol. 2019 Apr;185(2):342-344. doi: 10.1111/bjh.15455. Epub 2018 Jun 25. Br J Haematol. 2019. PMID: 29938774 Free article. No abstract available.
Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology.
Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R. Kumar SK, et al. Among authors: reu fj. J Natl Compr Canc Netw. 2017 Feb;15(2):230-269. doi: 10.6004/jnccn.2017.0023. J Natl Compr Canc Netw. 2017. PMID: 28188192
Adding Cyclophosphamide to Bortezomib and Dexamethasone was not Associated With Improved Outcomes of Patients With Newly Diagnosed Light Chain Amyloidosis: A Retrospective Study.
Zhang Y, Duncanson L, Brayer J, Reu F, Hansen D, Alsina M, Nishihori T, Ochoa-Bayona J, Liu H, Shain K, Thompson Z, Baz R, Blue B. Zhang Y, et al. Among authors: reu f. Clin Lymphoma Myeloma Leuk. 2022 Aug;22(8):e770-e776. doi: 10.1016/j.clml.2022.04.003. Epub 2022 Apr 8. Clin Lymphoma Myeloma Leuk. 2022. PMID: 35504808 Free PMC article.
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Benboubker L, et al. N Engl J Med. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551. N Engl J Med. 2014. PMID: 25184863 Free article. Clinical Trial.
37 results